-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Naltrexone in Migraine
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Naltrexone in Migraine report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Naltrexone in Migraine Drug Details: Naltrexone is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AZD-0780 in Cardiovascular Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AZD-0780 in Cardiovascular Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AZD-0780 in Cardiovascular Disease Drug Details: AZD-0780 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Acetaminophen + Naltrexone) in Chronic Low Back Pain (CLBP)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Acetaminophen + Naltrexone) in Chronic Low Back Pain (CLBP) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Acetaminophen + Naltrexone) in Chronic Low...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CTX-131 in Metastatic Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CTX-131 in Metastatic Renal Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CTX-131 in Metastatic Renal Cell Carcinoma Drug Details: CTX-131 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BP-1002 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BP-1002 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BP-1002 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ibrutinib in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ibrutinib in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ibrutinib in Metastatic Melanoma Drug Details: Ibrutinib (Imbruvica) is an anti-neoplastic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Naltrexone in Psychiatric Disorders
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Naltrexone in Psychiatric Disorders Drug Details: Naltrexone is under development for the treatment of postherpetic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Naltrexone in Migraine
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Naltrexone in Migraine Drug Details: Naltrexone is under development for the treatment of postherpetic neuralgia,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Clonidine + Naltrexone) in Chronic Low Back Pain (CLBP)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Clonidine + Naltrexone) in Chronic Low Back Pain (CLBP) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Clonidine + Naltrexone) in Chronic Low Back...
-
Product Insights
Postherpetic Neuralgia – Drugs In Development, 2023
Global Markets Direct’s, ‘Postherpetic Neuralgia - Drugs In Development, 2023’, provides an overview of the Postherpetic Neuralgia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Postherpetic Neuralgia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...